Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/16/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Peter Mueller?

Peter R. Mueller

Senior Vice President, Research and Development

Boehringer Ingelheim Corporation

HQ Phone:  (905) 639-0333

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Boehringer Ingelheim Corporation

5180 South Service Road

Burlington, Ontario,L7L 5H4

Canada

Company Description

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, foun... more

Find other employees at this company (9,206)

Background Information

Employment History

President

R&D Companies


President of Research and Development and CSO

Axcella Health Inc


President

Epicenter Consulting LLC


Chief Scientific Officer and Executive Vice President of Global Research and Development

Vertex Inc


President of Research and Development and CSO

Pronutria Biosciences Inc


Chief Operating Officer

Amarillo Biosciences , Inc.


Vice President, Global Marketing and Medical Information and Technology

Aventis SA


Director of Global Commercial Development

Merrell Dow


Affiliations

USA India Chamber of commerce

Advisory Board Member


Inhibikase Therapeutics Inc

Board Member


Gesellschaft Deutscher Chemikere

Board Member


Govenor Roland

Member of Council On Economic Competitiveness and Technology for the State of Connecticut


Phacilitate Limited

Advisory Board Member


Keystone Symposia

Scientific Advisory Board Member


Biosensor Forum

Advisory Board Member


GDS International Ltd

Delegate


Albert Einstein University of Ulm , Germany

Faculty Member


American Association for the Advancement of Science

Member


Royal Society of Chemistry

Member


The RNA Society

Member


Education

MBA

Babson


Ph.D.

Pharmacology

University of Mainz


PhD

Chemistry

Albert Einstein University of Ulm , Germany


undergraduate degree

Albert Einstein University of Ulm , Germany


Web References(132 Total References)


Board of Directors | Inhibikase Therapeutics, Inc.

www.inhibikase.com [cached]

Peter Mueller, PhD.
Dr. Mueller joined Vertex in July 2003. As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs. Key areas of Vertex' R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas. Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Peter Mueller, PhD | Axcella Health, Inc

www.axcellahealth.com [cached]

Peter Mueller, PhD
President of R&D and Chief Scientific Officer Prior to his time at Axcella, Dr. Peter Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible for the build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, as well as Clinical and Non-Clinical Development, Regulatory and Medical Affairs and Patient Safety. Key areas of Vertex's R&D have been hepatitis C (HepC), cystic fibrosis (CF), Immune Mediated Intestinal Diseases (IMID), cancer and neurological diseases. His leadership led to the successful approval and launch of two breakthrough drugs, INCIVEK (HepC) in 2011, and KALYDECO (CF) in 2012, as well as a, NDA and MAA for Orkambi (CF) and numerous sNDA submissions for KALYDECO (CF) and several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA). Both Breakthrough Therapies got awarded the prestigious Prix Galien award (U.S., Telaprevir) and its European counterpart the Galenus Preis (Kalydeco). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for research in North America and the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim (BI), starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies. He is a Board member of various scientific and political societies, such as the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.); U.S.-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Inhibikase, Visterra and Kaleido. He has also supported the Harvard Accelerator Fund, the Scientific Advisory Board for Keystone Conferences, and the Governor Roland's Council on Economic Competitiveness and Technology for the State of Connecticut (USA).


Peter Mueller, Ph.D., President of R&D and Chief Scientific Officer , Pronutria BioSciences LLC

usaindiachamber.org [cached]

Peter Mueller, Ph.D.
President of R&D and Chief Scientific Officer Pronutria BioSciences LLC In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer. Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB). Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Convergence: The Life Sciences Leaders Forum

www.convergenceforum.com [cached]

Peter Mueller, PhD
Convergence: The Life Sciences Leaders Forum Peter Mueller PhD Dr. Mueller currently serves as our Executive Vice President, Global Research and Development, and Chief Scientific Officer, a position he assumed in May 2009. Dr. Mueller has been with Vertex since 2003. He is responsible for Vertex's research and development, including clinical and non-clinical development, clinical operations and medical and regulatory affairs for all of Vertex's drug candidates. Prior to joining Vertex, Dr. Mueller was the Senior Vice President, Research and Development, of Boehringer Ingelheim Pharmaceuticals, Inc., with responsibility for the development of all drug candidates in the company's worldwide portfolio in North America. In the US he also led research programs in the areas of immunology, inflammatory cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery, development and approval of numerous development candidates and held several positions in basic research, medicinal chemistry and management. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretic Organic Chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University.


www.essentientinc.com

CAMBRIDGE, Mass., Dec. 4, 2014 /PRNewswire/ -- Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, announced today that Peter Mueller, Ph.D., has been appointed President of Research and Development and Chief Scientific Officer.
Dr. Mueller will lead Pronutria's efforts to discover and develop products to maintain health and treat a variety of serious medical conditions across a wide spectrum of indication areas including skeletal muscle, metabolic, gastrointestinal, neurodegenerative and rare diseases. Pronutria is transforming health by unlocking the potential of homeostatic amino acid biology. Pronutria has developed a proprietary library with over one billion orally available proteins and the tools to select, validate and express them to elicit specific physiologic benefits. When delivered orally, product candidates release temporally controlled amino acid supplies that can impact health and disease. "Peter is one of the most accomplished scientific and visionary leaders in the pharmaceutical industry," said Robert Connelly, CEO of Pronutria. "Amino acids are fundamental in the regulation of cellular processes for maintaining health throughout the body," said Dr. Mueller. "A wide range of diseases with serious unmet medical needs are impacted by maladapted amino acid homeostasis, which can come from injury, disease, aging and therapeutic intervention. Leveraging this key underappreciated biology gives Pronutria a powerful handle to affect health and disease. I am excited to join the team of world-class scientists at Pronutria, and look forward to working with the team in restoring amino acid imbalance to fundamentally transform the lives of people with severe, debilitating and degenerative medical conditions." Prior to Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer for Vertex Pharmaceuticals Inc., where he provided strategic oversight for Vertex's worldwide drug discovery and development programs, with specific emphasis in Hepatitis C, cystic fibrosis, immune-mediated inflammatory diseases, cancer and neurological diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK® (Hepatitis C), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO® (cystic fibrosis) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both breakthrough therapies were awarded the prestigious Prix Galien award (US, INCIVEK®) or its European counterpart the Galenus Preis (KALYDECO®). Previously, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. His leadership was instrumental in the global development of Spiriva®, Combivent® and Atrovent®. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of Boehringer Ingelheim worldwide. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory